Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2014-07-28 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release dated July 28, 2014, announcing the publication of Phase 2 clinical trial results for the drug Masitinib in the treatment of GIST in the 'Annals of Oncology' journal. It details positive efficacy and safety data, quotes key researchers, and mentions that a Phase 3 study is underway. This content is characteristic of an announcement regarding clinical trial results and scientific findings, often released to the public and investors before or alongside a formal regulatory filing. Since it is a detailed announcement of results and not a formal regulatory report (like 10-K, IR, or AR), and it is not a transcript (CT) or a general investor presentation (IP), the most fitting category is 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'Earnings Release' (ER) if it were tied to a quarterly period, but here it is purely scientific/clinical news. Given the options, and that it is a specific announcement of scientific data publication, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, material corporate news that isn't a standard financial report or presentation. However, since it is a detailed announcement of clinical trial results, it is often classified as a general corporate communication. Given the available codes, RNS is the most appropriate fallback for a material, non-financial-report announcement.
2014-07-28 French
AB Science EN
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science dated July 28, 2014, detailing the publication of results from a randomized phase 2 study of masitinib in the journal 'Annals of Oncology'. It summarizes key findings (survival advantages, safety profile) and mentions that a larger phase 3 trial has been initiated based on these results. This is a press release announcing clinical trial results and publication, which typically falls under general corporate or investor news. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific financial event announcement (like DIV or CAP), and it is not a transcript (CT) or a management discussion (MDA), the most appropriate category is a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a news release. Given the options, and that it is a formal announcement of scientific progress rather than a financial report, RNS (Regulatory Filings/General Announcement) is the best fit, as it is a significant corporate update that doesn't fit the specific financial report codes. It is not short enough to strictly qualify for RPA based on the 'Menu vs Meal' rule, as it contains substantial detail about the study, though it is announcing an external publication.
2014-07-28 English
AB Science FR
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "Résultats de l'Assemblée Générale Mixte du 27 juin 2014" (Results of the Combined General Meeting of June 27, 2014) and contains detailed tables showing the results of various resolutions voted upon by shareholders (e.g., approval of accounts, capital increases, remuneration). This content directly relates to the outcomes of a shareholder meeting. The most specific category for official results from shareholder votes at any general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the focus is on the *results* of the votes, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2014-07-01 French
AB Science FR
Legal Proceedings Report Classification · 95% confidence The document is a press release dated May 22, 2014, announcing a negative opinion from the CHMP (Committee for Human Medicinal Products) of the EMA regarding the conditional marketing authorization for masitinib for pancreatic cancer treatment. It details the regulatory process, the reasons for the negative opinion (reliance on subgroup analysis), and the company's plan to file based on confirmatory Phase 3 study data. This content is a specific update on a regulatory/legal matter concerning a drug application and subsequent appeal outcome. It is not a full Annual Report (10-K), an Earnings Release (ER), a general Investor Presentation (IP), or a standard Audit Report (AR). It most closely aligns with reporting on significant legal/regulatory proceedings or outcomes, fitting best under Legal Proceedings Report (LTR), as it concerns the outcome of a regulatory review process and subsequent legal/procedural steps (appeal, intent to refile). It is too specific for a general Regulatory Filing (RNS) and does not fit any other category.
2014-05-22 French
AB Science EN
Legal Proceedings Report Classification · 95% confidence The document is an announcement dated May 22, 2014, detailing a negative opinion received from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the conditional marketing authorization for Masitinib in pancreatic cancer. It discusses regulatory feedback, subgroup analysis, safety profiles, and the company's intention to file for full approval based on future Phase 3 data. This content relates to significant legal/regulatory outcomes concerning a drug's approval status, which falls under 'Legal Proceedings Report' (LTR) as it concerns regulatory action and legal/approval hurdles, or potentially 'Regulatory Filings' (RNS) if LTR is too narrow. Given the focus on a specific regulatory decision (CHMP opinion on appeal) and the company's response to that regulatory action, LTR is the most specific fit among the provided options, as it deals with significant legal/regulatory matters impacting the business, even if not a traditional lawsuit. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS) since it addresses a specific, material regulatory event.
2014-05-22 English
AB Science FR
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 point 2 f and 223-16 of the AMF General Regulation (Autorité des Marchés Financiers). It provides a table showing the total number of shares and voting rights as of a specific date (April 30, 2014). This content directly relates to reporting changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it details the total number of shares and associated voting rights, a key component of capital structure reporting. Although it is a monthly report, it is not a comprehensive financial report (IR) or an earnings release (ER). It is a specific regulatory disclosure about the capital base.
2014-05-16 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.